InSyBio

InSyBio, founded in 2013, is a pioneering biotechnology company based in the United States, focusing on personalized healthcare and nutrition. Known for being a disruptive force in Precision Medicine & Nutrition, InSyBio leverages machine-learning to develop advanced computational tools for analyzing complex life-science and biological data.

The company revolutionizes the personalization of nutrition and health products through its InSyBio Personalization Test, which predicts consumer outcomes prior to purchase, enhancing both satisfaction and effectiveness. InSyBio’s core product, the InSyBio Suite, aids researchers by reducing time and costs for biomedical data analyses while increasing outcome prediction accuracy.

With services recognized in international scientific journals and patents pending, InSyBio's platform decreases cost requirements by 80% and boosts predictive model accuracy by 10%. Recently, the company secured a $100.00K Series A investment from Loyal VC in July 2023, indicating strong market confidence. InSyBio's participation in the NBG Business Seeds program further underscores its growth potential in the AI, Biotechnology, and Health sectors.